CliffBio
biologic

Nuwiq

Antihemophilic Factor (Recombinant)

Loss of exclusivitySeptember 2027projected — 12-year biologic exclusivity estimate
CompanyOctapharma Pharmazeutika Produktionsges.m.b.H.

Drug detail

Brand nameNuwiq
Active ingredientAntihemophilic Factor (Recombinant)
Strength500IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2015
Marketing statusRx

More from Octapharma Pharmazeutika Produktionsges.m.b.H.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Nuwiq patent cliff — loss of exclusivity September 2027 | CliffBio